Spero Therapeutics Chief Medical Officer David Melnick receives $1.6M in 2018
Spero Therapeutics reports 2018 executive compensation
By ExecPay News
Published: September 30, 2020
Spero Therapeutics reported fiscal year 2018 executive compensation information on September 30, 2020.
In 2018, four executives at Spero Therapeutics received on average a compensation package of $856K, a 50% decrease compared to previous year.
Average pay of disclosed executives at Spero Therapeutics
David Melnick, Chief Medical Officer, received $1.6M in total. 66% of Melnick's compensation, or $1.1M, was in option awards. Melnick also received $10K in bonus, $146K in non-equity incentive plan, $376K in salary, as well as $20K in other compensation.
Ankit Mahadevia, Chief Executive Officer, received a compensation package of $721K, which decreased by 77% compared to previous year. 64% of the compensation package, or $465K, was in salary.
Christina Larkin, Chief Operating Officer, earned $534K in 2018, a 56% decrease compared to previous year.
Cristina Larkin, Chief Operating Officer, received $534K in 2018, which decreases by 56% compared to 2017.
Related executives
You may also like
Source: SEC filing on September 30, 2020.